Findings show growing optimism across the pharma sector as dealmaking accelerates, innovation strengthens, and companies adapt to tariffs, pricing reforms, and looming patent expirations
MabionCD20 is a monoclonal antibody originally developed by Mabion as a biosimilar candidate to MabThera and Rituxan therapies
Phase 1 study to evaluate Siglec-6-targeted CAR-T therapy in relapsed or refractory AML and CLL patients, marking a major milestone for T-CURX’s scalable non-viral CAR-T platform
New hit discovery service combines integrated DNA-Encoded Library screening, structural biology, biophysics, and X-ray crystallography
The graduating cohort comprised seven batches across five specialized programs
Independent DSMB recommends continuation of Masupirdine without modifications as enrollment reaches 88% in global trial
MSD joins as anchor customer as Aurobindo strengthens its position in the fast-growing global biologics manufacturing market
Teva said the launch strengthens its biosimilars strategy and expands access to biologic medicines across Europe
Anti-GD2 monoclonal antibody for high-risk neuroblastoma advances toward BLA submission following successful tech transfer from California to Bengaluru
Madhav Bhutada says overdependence on large CDMOs and delayed engagement can increase development costs by up to 40% and slow clinical progress
The company intends to file an IND submission by the end of this year and begin clinical studies in 2027
The next-generation proteomics platform powered by Olink™ Explore HT enables simultaneous analysis of thousands of proteins from a single sample
Tecentriq SC reduces treatment administration time by nearly 80 percent and has the potential to lower indirect treatment costs
Ex-US revenue rose sharply by 21% YoY to Rs. 2, 240.4 crore ($254 million); Operational PAT grew 50.3% YoY to Rs. 518.1 crore
Funding to support clinical development, gene therapy pipeline expansion and GMP manufacturing capabilities
Lormalzi is the first and only once-monthly amyloid plaque-targeting therapy with clinical evidence
The two companies will establish a joint Center of Excellence (CoE) in Bengaluru
The biosimilars business generated Rs. 10,431 crore in FY26 revenue, up 16% year-on-year
The company highlights role of integrated genomics and multi-omics research at the Illumina Multiomics Summit India 2026 held in New Delhi and Bengaluru
As per GlobalData, CARsgen’s satri-cel could mark a major breakthrough in solid tumor treatment as competition intensifies
Subscribe To Our Newsletter & Stay Updated
